Allogene Therapeutics (ALLO) Preferred Shares Issued (2018)
Allogene Therapeutics recorded quarterly Preferred Shares Issued of -$1000.0 in Q4 2018, down 100.0% quarter-over-quarter from $150.0 million in Q3 2018.
Allogene Therapeutics' Preferred Shares Issued history runs 1 years deep, the most recent figure standing at -$1000.0 for Q4 2018.
- In Q4 2018, Preferred Shares Issued changed N/A year-over-year to -$1000.0; the TTM figure through Dec 2019 stood at $150.0 million (changed N/A YoY), while the FY2018 annual figure was $299.3 million, changed N/A from the prior year.
- Preferred Shares Issued came in at -$1000.0 for Q4 2018 at Allogene Therapeutics, down from $150.0 million in the prior quarter.
- In the past five years, Preferred Shares Issued ranged from a high of $150.0 million in Q3 2018 to a low of -$115.1 million in Q2 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares Issued (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Allogene Therapeutics | 521.43 Mn | 521.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -1,000.00 |
| Dec 31, 2018 | -1,000.00 |
| Sep 30, 2018 | 150.00 Mn |
| Sep 30, 2018 | 150.00 Mn |
| Jun 30, 2018 | -115.12 Mn |
| Jun 30, 2018 | -115.12 Mn |